<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Chlorodiazepoxide - Complete Profile</title>
    <link rel="stylesheet" href="/style.css">
</head>

<body>
  <body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/" class="site-title">Dyo's Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/">Home</a>
          </li>
          <li>
            <a href="/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/about/">About</a>
          </li>
          <li>
            <a href="/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/depressants/">Depressants</a> ‚Üí <span>Chlorodiazepoxide</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üíä Chlorodiazepoxide</h1>
        <h2 class="chemical-name">7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepin-4-oxide</h2>
        
        <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Chlorodiazepoxide" 
                data-category="Depressants" 
                data-chemical="7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepin-4-oxide">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <span class="name-tag brand">Librium</span>
            <span class="name-tag brand">Librax</span>
            <span class="name-tag brand">Libritabs</span>
            <span class="name-tag brand">Mitran</span>
            <span class="name-tag brand">Poxi</span>
            <span class="name-tag chemical">CDO</span>
            <span class="name-tag chemical">Methaminodiazepoxide</span>
            <span class="name-tag street">Libs</span>
            <span class="name-tag street">Greens</span>
            <span class="name-tag street">Green and blacks</span>
            <span class="name-tag medical">Chlordiazepoxide HCl</span>
            <span class="name-tag historical">Original benzo</span>
            <span class="name-tag clinical">First benzodiazepine</span>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category depressant">Depressant</span>
          <span class="legal-status schedule-4">Schedule IV</span>
          <span class="duration long">24-48 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/chlorodiazepoxide.jpg" alt="Chlorodiazepoxide capsules and tablets" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>Molecular structure of chlorodiazepoxide showing the characteristic benzodiazepine core with chlorine substitution</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pharmaceutical Forms</h4>
          <ul>
            <li><strong>Capsules:</strong> Green and black (5mg), green and yellow (10mg), green and white (25mg)</li>
            <li><strong>Tablets:</strong> White to off-white, scored, various strengths</li>
            <li><strong>Powder:</strong> White to pale yellow crystalline powder (pharmaceutical grade)</li>
            <li><strong>Injectable:</strong> Clear solution for intramuscular use (100mg/5mL ampules)</li>
            <li><strong>Solubility:</strong> Sparingly soluble in water, freely soluble in alcohol</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Common Preparations</h4>
          <ul>
            <li><strong>Librium capsules:</strong> Most common form, distinctive green coloring</li>
            <li><strong>Generic tablets:</strong> Various manufacturers, white/pale colored</li>
            <li><strong>Combination products:</strong> Often combined with clidinium bromide (Librax)</li>
            <li><strong>Counterfeit pills:</strong> Rare but may contain other benzodiazepines</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Identification Notes</h4>
          <p><strong>Legitimate sources:</strong> Always pharmaceutical preparations with clear markings</p>
          <p><strong>Counterfeits:</strong> Extremely rare due to low street value and medical availability</p>
          <p><strong>Cross-contamination:</strong> May be confused with other green capsules (temazepam, etc.)</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">2.5-5mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">5-10mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">10-25mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">25-50mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">50mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Medical Dosage Guidelines</h4>
        <ul>
          <li><strong>Anxiety:</strong> 5-25mg 3-4 times daily</li>
          <li><strong>Alcohol withdrawal:</strong> 50-100mg initial, then 25-50mg every 2-4 hours as needed</li>
          <li><strong>Preoperative anxiety:</strong> 5-10mg administered 3-4 hours before surgery</li>
          <li><strong>Elderly patients:</strong> Reduced dosage (5mg 2-4 times daily maximum)</li>
          <li><strong>Hepatic impairment:</strong> Significantly reduced dosing required</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Critical Warning:</strong> Extremely long half-life (24-48 hours) means effects accumulate with repeated dosing. Risk of severe withdrawal and potentially fatal seizures with discontinuation.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-2:00</span>
          <span class="effect">Onset - gradual anxiety reduction, mild sedation</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+2:00-8:00</span>
          <span class="effect">Peak - maximum anxiolytic and sedative effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+8:00-24:00</span>
          <span class="effect">Plateau - sustained therapeutic effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+24:00-72:00</span>
          <span class="effect">Comedown - gradual elimination, potential rebound anxiety</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Therapeutic Effects</h4>
          <ul>
            <li>Profound anxiety relief and calmness</li>
            <li>Muscle relaxation and tension relief</li>
            <li>Anticonvulsant protection</li>
            <li>Alcohol withdrawal symptom control</li>
            <li>Sleep improvement and insomnia relief</li>
            <li>Panic attack prevention</li>
            <li>Reduced agitation and restlessness</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Adverse Effects</h4>
          <ul>
            <li>Excessive daytime sedation and drowsiness</li>
            <li>Cognitive impairment and memory problems</li>
            <li>Motor coordination difficulties</li>
            <li>Dependency and withdrawal syndrome</li>
            <li>Rebound anxiety between doses</li>
            <li>Confusion and disorientation (especially elderly)</li>
            <li>Respiratory depression (high doses/combinations)</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Chlorodiazepoxide acts as a positive allosteric modulator of GABA-A receptors, the brain's primary inhibitory neurotransmitter system. By binding to the benzodiazepine site on GABA-A receptors, it enhances the receptor's affinity for GABA, increasing chloride ion influx and neuronal hyperpolarization. This results in widespread CNS depression with anxiolytic, sedative, anticonvulsant, and muscle relaxant properties.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor">GABA-A (Œ±1Œ≤2Œ≥2)</span>
            <span class="affinity">High affinity</span>
            <span class="effect">Positive allosteric modulation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">GABA-A (Œ±2Œ≤2Œ≥2)</span>
            <span class="affinity">High affinity</span>
            <span class="effect">Anxiolytic effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">GABA-A (Œ±3Œ≤2Œ≥2)</span>
            <span class="affinity">Moderate affinity</span>
            <span class="effect">Muscle relaxation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">GABA-A (Œ±5Œ≤2Œ≥2)</span>
            <span class="affinity">Low affinity</span>
            <span class="effect">Memory impairment</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> Hepatic N-demethylation via CYP3A4 ‚Üí N-desmethylchlorodiazepoxide (active)</p>
          <p><strong>Secondary Pathway:</strong> Further metabolism to demoxepam (active) ‚Üí oxazepam (active) ‚Üí glucuronidation</p>
          <p><strong>Half-life:</strong> 24-48 hours (parent compound), active metabolites extend duration significantly</p>
          <p><strong>Bioavailability:</strong> 90% oral, 100% intramuscular</p>
          <p><strong>Peak plasma:</strong> 1-4 hours oral, 15-30 minutes IM</p>
          <p><strong>Protein binding:</strong> 90-98% bound to albumin</p>
          <p><strong>Elimination:</strong> Primarily renal excretion of metabolites</p>
        </div>

        <h4>Active Metabolites</h4>
        <div class="metabolites-info">
          <p><strong>N-desmethylchlorodiazepoxide:</strong> Equipotent anxiolytic, half-life 18-50 hours</p>
          <p><strong>Demoxepam:</strong> Active anxiolytic metabolite, half-life 14-95 hours</p>
          <p><strong>Oxazepam:</strong> Final active metabolite, half-life 3-25 hours</p>
          <p><strong>Clinical significance:</strong> Multiple active metabolites create extremely prolonged effects and accumulation risk</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>First benzodiazepine:</strong> Discovered in 1955, established the entire drug class</li>
          <li><strong>Long-acting profile:</strong> Ideal for alcohol withdrawal and chronic anxiety management</li>
          <li><strong>Low abuse potential:</strong> Slower onset and less euphoric than shorter-acting benzodiazepines</li>
          <li><strong>Anticonvulsant activity:</strong> Effective seizure prevention, especially alcohol withdrawal seizures</li>
          <li><strong>Age-related sensitivity:</strong> Dramatically increased sensitivity and impairment in elderly patients</li>
          <li><strong>Hepatic metabolism dependency:</strong> Severely impaired clearance in liver disease</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Respiratory depression:</strong> Life-threatening when combined with alcohol or opioids</li>
            <li><strong>Withdrawal seizures:</strong> Potentially fatal - requires medical supervision to discontinue</li>
            <li><strong>Rapid tolerance:</strong> Develops within days to weeks of regular use</li>
            <li><strong>Cognitive impairment:</strong> Severe memory and learning deficits, especially long-term use</li>
            <li><strong>Fall risk:</strong> Extreme caution in elderly - high fracture risk from sedation</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Precautions</h4>
          <ul>
            <li><strong>Never stop abruptly:</strong> Always taper dosage slowly under medical supervision</li>
            <li><strong>Avoid alcohol:</strong> Dangerous potentiation of CNS depression</li>
            <li><strong>Driving impairment:</strong> Severely compromised motor skills and reaction time</li>
            <li><strong>Drug accumulation:</strong> Effects build up with repeated dosing due to long half-life</li>
            <li><strong>Liver function:</strong> Regular monitoring required for long-term use</li>
            <li><strong>Pregnancy risk:</strong> Category D - potential for fetal harm and neonatal withdrawal</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Severe respiratory insufficiency, sleep apnea, severe liver disease, myasthenia gravis, acute narrow-angle glaucoma, or known hypersensitivity to benzodiazepines.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous</h4>
          <ul>
            <li><strong>Alcohol:</strong> Severe respiratory depression, coma, death</li>
            <li><strong>Opioids:</strong> Life-threatening respiratory depression</li>
            <li><strong>Barbiturates:</strong> Additive CNS depression, respiratory failure</li>
            <li><strong>Other benzodiazepines:</strong> Dangerous additive effects and overdose risk</li>
            <li><strong>Z-drugs (zolpidem, etc.):</strong> Severe sedation and respiratory depression</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Risky</h4>
          <ul>
            <li><strong>Antihistamines:</strong> Increased sedation and cognitive impairment</li>
            <li><strong>Antipsychotics:</strong> Enhanced CNS depression</li>
            <li><strong>Muscle relaxants:</strong> Additive motor impairment</li>
            <li><strong>Anticonvulsants:</strong> Altered seizure threshold and metabolism</li>
            <li><strong>Tricyclic antidepressants:</strong> Increased sedation and anticholinergic effects</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Caution</h4>
          <ul>
            <li><strong>CYP3A4 inhibitors:</strong> Ketoconazole, erythromycin increase levels</li>
            <li><strong>Grapefruit juice:</strong> May increase absorption and effects</li>
            <li><strong>Smoking:</strong> May decrease effectiveness through enzyme induction</li>
            <li><strong>Cimetidine:</strong> Inhibits metabolism, increases toxicity risk</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <strong>United States:</strong> Schedule IV Controlled Substance - prescription required
          </div>
          <div class="jurisdiction">
            <strong>United Kingdom:</strong> Class C Controlled Drug - prescription only medicine
          </div>
          <div class="jurisdiction">
            <strong>Canada:</strong> Schedule IV - prescription required, targeted substance
          </div>
          <div class="jurisdiction">
            <strong>Australia:</strong> Schedule 4 - prescription only medicine
          </div>
        </div>
        
        <div class="therapeutic-status">
          <h4>üè• Medical Applications</h4>
          <p>Chlorodiazepoxide remains widely prescribed for anxiety disorders, alcohol withdrawal management, and preoperative sedation. It's considered a first-line treatment for alcohol detoxification due to its long duration of action and reduced seizure risk compared to shorter-acting benzodiazepines.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1955</span>
          <p>Synthesized by Leo Sternbach at Hoffmann-La Roche, initially shelved as inactive</p>
        </div>
        <div class="history-event">
          <span class="year">1957</span>
          <p>Accidental discovery of anxiolytic properties during laboratory cleanup</p>
        </div>
        <div class="history-event">
          <span class="year">1960</span>
          <p>FDA approval and market introduction as Librium - first benzodiazepine</p>
        </div>
        <div class="history-event">
          <span class="year">1963</span>
          <p>Diazepam (Valium) developed as improved successor</p>
        </div>
        <div class="history-event">
          <span class="year">1970s</span>
          <p>Peak popularity for anxiety treatment before dependence risks recognized</p>
        </div>
        <div class="history-event">
          <span class="year">1988</span>
          <p>Moved to Schedule IV due to abuse and dependence concerns</p>
        </div>
        <div class="history-event">
          <span class="year">Present</span>
          <p>Still prescribed but with greater awareness of addiction potential</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Medical Impact</h4>
        <p>Chlorodiazepoxide revolutionized anxiety treatment and established the benzodiazepine class that would become one of the most prescribed drug categories in medical history. Its discovery marked the transition from barbiturates to safer anxiolytics, though long-term dependency risks were not initially understood.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Alcohol Withdrawal Protocols</h4>
          <p>Ongoing research into optimal dosing protocols for alcohol detoxification, comparing fixed-dose versus symptom-triggered regimens to minimize treatment duration while preventing complications.</p>
        </div>
        
        <div class="research-item">
          <h4>Cognitive Effects in Aging</h4>
          <p>Studies examining the relationship between long-term benzodiazepine use and dementia risk, particularly focusing on chlorodiazepoxide's prolonged active metabolites in elderly populations.</p>
        </div>
        
        <div class="research-item">
          <h4>Safer Alternatives</h4>
          <p>Research into GABA-A receptor subtype-selective compounds that could provide anxiolytic effects without the cognitive impairment and dependence liability of traditional benzodiazepines.</p>
        </div>
        
        <div class="research-item">
          <h4>Withdrawal Management</h4>
          <p>Development of evidence-based tapering protocols and adjunct medications to ease benzodiazepine discontinuation and prevent protracted withdrawal syndrome.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><a href="https://www.drugs.com/librium.html">Drugs.com Librium Guide</a></li>
          <li><a href="https://dailymed.nlm.nih.gov/dailymed/">FDA Drug Labels (DailyMed)</a></li>
          <li><a href="https://www.rxlist.com/librium-drug.htm">RxList Professional Information</a></li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Withdrawal Support</h4>
        <ul>
          <li><a href="https://www.benzoinfo.com/">Benzodiazepine Information Coalition</a></li>
          <li><a href="https://www.benzo.org.uk/">Professor Ashton's Manual</a></li>
          <li><a href="https://www.survivingantidepressants.org/">Surviving Antidepressants Forum</a></li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Professional Resources</h4>
        <ul>
          <li><a href="https://www.samhsa.gov/">SAMHSA Treatment Locator</a></li>
          <li><a href="https://www.asam.org/">American Society of Addiction Medicine</a></li>
          <li><a href="https://www.niaaa.nih.gov/">NIAAA Alcohol Resources</a></li>
        </ul>
      </div>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/js/lunr.min.js"></script>
    <script src="/assets/js/search.js"></script>
    <script src="/assets/js/substance-integration.js"></script>
</body>
</html>